Business
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms.
About this update from Marijuana Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms\r\n \r\n \r\n\r\n\r\nExousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms\r\n\r\n\r\n\r\n\r\n\r\nORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the execution of an exclusive licensing agreement between its wholly owned subsidiary, Exousia Pro Holding Management, LLC, and the University of Central Florida (UCF) concerning its groundbreaking technology for both the diagnosis and treatment of cancer using exosomes.\r\n Securing Foundational, Worldwide Intellectual Property\r\n The agreement grants Exousia Pro Holding Management (EPHM) an exclusive license to UCF-developed patented and patent-pending intellectual property. This robust intellectual property portfolio includes:\r\n \r\n Exosomal NANOG DNA as a Diagnostic Cancer Marker: This key technology is protected by a U.S. Patent (US011193174B2) granted on December 7, 2021, focusing on the use of Exosomal NANOG DNA for cancer screening.\r\n Exosomal Delivery Platform for Therapy: A comprehensive system for the delivery of gene expression modulating agents for therapy against cancer and viral infection, with patent applications pending across multiple critical jurisdictions, including the U.S., Canada, China, Europe, and Japan.\r\n \r\n This exclusive, global licensing strategy ensures Exousia Pro maintains a dominant position over foundational technologies essential for developing next-generation exosome-based diagnostics and therapeutics.\r\n Game-Changing Diagnostic Potential: Detecting Rare Silent Killer Cancers\r\n The licensed technology incorporates the development of a proprietary NANOG DNA cancer screening test. This test is positioned as a game-changing, non-invasive diagnostic tool with the ability to detect a wide spectrum of cancers, including rare, highly aggressive malignancies often referred to as \"silent killer\" cancers due to their late-stage presentation.\r\n The test offers several competitive advantages in the field of liquid biopsy:\r\n \r\n Universal Scree...